Antipyretic drugs :: Consumers survey results of 2006

Consumers survey results of 2006 in category

Cold and Flu / Antipyretic drugs

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.	2	Колдрекс (GlaxoSmithKline)	25.45%	5

2.	7	Мілістан (Mili Healthcare)	29.09%	4.71

–.	3	~~АЦЦ~~	~~8.18%~~	~~3.97~~

3.	5	Терафлю (Novartis OTC)	18.18%	3.27

4.	5	Панадол (GlaxoSmithKline)	16.36%	3.25

5.	1	Упсарин Упса (Bristol-Myers Squibb)	17.27%	2.81

6.	4	Парацетамол	15.45%	2.79

7.	4	Ефералган (Bristol-Myers Squibb)	12.73%	2.61

8.	7	Найз	4.55%	2.21

9.		Німесулід	2.73%	1.32

10.		Колдакт Флю Плюс (Ranbaxy)	5.45%	1.12

11.	7	Гриппостад (Nizhpharm)	5.45%	1.01

12.	~	Ibuprom (EU Pharmacia)	4.55%	0.99

13.		Німегезік	0.91%	0.44

14.		Колдрін (Teva)	1.82%	0.29

15.	6	Antiflu (Bayer)	1.82%	0.28

16.	~	Інсті (Herbion)	0.91%	0.13

–.		Німесин плюс	0.00%	0

The participant which took the 1st place in this rating is by opinion of Ukrainian consumers is the best choice in 2006, recommendation of consumers #1 in the category “Antipyretic drugs”.

Using this rating is only possible with obligatory link to the source.

This rating was built as a result of the study of social preferences in 2006, under the “Favorites of Success” Contest in Ukraine and it’s the free information. In case of full or partial republishing of the information drawn from this rating, it is obligatory to mention the name of the “Favorites of Success” Contest in printed publications, or put an active hyperlink to this page in the electronic media.

Advanced reporting booklet about the study, including demographics of the respondents, by regional breakdown, information roll-call of ad hoc judges etc, can also be obtained from managers of the contest.